Loading the company…
Loading the company…
Families: Thrombectomy, IVC filters & venous stents.
All companies · Product and company coverage
In the last ten years FDA made 7 decisions for Imperative Care (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2025 (3). The latest was on 2025-10-30.
| Family | Decisions on record |
|---|---|
| Thrombectomy, IVC filters & venous stents | 7 |
In 2025, Imperative Care reported engagement with 2,444 surgeons and other clinicians in the states MedaRep covers, worth $1.0M in consulting, speaking, meals and travel for its device products, the most in New York ($244K to 166). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: New York ($244K, 166 engaged), Alabama ($140K, 20 engaged), Texas ($127K, 364 engaged), Florida ($64K, 214 engaged), California ($43K, 218 engaged).
| ZOOM (71, 55, 45, 35) Reperfusion Catheters; ZOOM Aspiration Tubing |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Imperative Care.